Las Vegas, NV -- (SBWIRE) -- 01/23/2014 -- Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental analysis, on NYSE, NASDAQ, AMEX, OTCBB and Pink Sheet Stocks. Let’s have a brief look at: Dynavax Technologies Corporation (NASDAQ:DVAX), Zynga Inc (NASDAQ:ZNGA), MELA Sciences Inc (NASDAQ:MELA), Keryx Biopharmaceuticals (NASDAQ:KERX).
Dynavax Technologies Corporation (NASDAQ:DVAX) ended its recent business day with the tumbled of -1.02% and closed at the price of $1.94 after opening at $1.99. The stock traded during its last trading session with the total volume of 5.84 million shares, as compared to its average volume of 5.09 million shares. Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases.
Has DVAX Found The Bottom And Ready To Gain Momentum? Find Out Here
Zynga Inc (NASDAQ:ZNGA) stock not showed any percentage change and stayed at 0.00% and traded with volume of 8.81 million shares in the last session, as compared to average volume of 16.91 million shares. In comparison with 52 week range of $2.40 - $4.55, it faced lowest price of $3.58 during the last trading session whereas its day highest price was $3.68. The company’s total market capitalization is $2.92 billion, along with 804.35 million shares outstanding. Zynga Inc. develops, markets, and operates online social games as live services on the Internet, social networking sites, and mobile platforms in the United States and internationally.
Can Investors Bet on ZNGA after this News update? Find Out Here
MELA Sciences Inc (NASDAQ:MELA) showed 3.75 million shares in volume during the last trading session, while the average trading volume remained 482,178.00 shares. The stock kicked off its trading session at $0.75 and closed at $0.720 after rallied 0.54%. MELA Sciences, Inc., a medical device company, designs, develops, and commercializes a non-invasive point-of-care instrument to aid in the detection of melanoma.
Why Should Investors Buy MELA After The Recent Gain? Just Go Here and Find Out
Keryx Biopharmaceuticals (NASDAQ:KERX) stock traded during its last trading session with the total traded volume of 5.83 million shares versus its average volume of 2.59 million shares. The company opened its trade at the price of $14.51 and its closing price was $14.60 after fell -5.07% for the day. Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States.
Has KERX Found The Bottom and Ready To Move Up? Find Out Here
PLEASE NOTE WELL: The employees of ValueStockPick.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site, Press releases or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Please Read Our Full Disclaimer at http://www.valuestockpick.com/disclaimer/
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)